ITMI20060050A1 - DERMOCOSMETIC COMPOSITION IN PARTICULAR FOR THE TREATMENT OF CUTANEOUS IRRITATION STATES THAT MAY BE ASSOCIATED WITH STATES OF OVER-INFECTION DERIVED FROM DSA SPECIFIC SKIN ALTERATIONS AND SPECIFICALLY OF THE CORNEO STATE - Google Patents
DERMOCOSMETIC COMPOSITION IN PARTICULAR FOR THE TREATMENT OF CUTANEOUS IRRITATION STATES THAT MAY BE ASSOCIATED WITH STATES OF OVER-INFECTION DERIVED FROM DSA SPECIFIC SKIN ALTERATIONS AND SPECIFICALLY OF THE CORNEO STATE Download PDFInfo
- Publication number
- ITMI20060050A1 ITMI20060050A1 ITMI20060050A ITMI20060050A1 IT MI20060050 A1 ITMI20060050 A1 IT MI20060050A1 IT MI20060050 A ITMI20060050 A IT MI20060050A IT MI20060050 A1 ITMI20060050 A1 IT MI20060050A1
- Authority
- IT
- Italy
- Prior art keywords
- substance
- composition according
- states
- composition
- epitalizing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 40
- 230000004075 alteration Effects 0.000 title claims description 8
- 208000015181 infectious disease Diseases 0.000 title claims description 8
- 230000007794 irritation Effects 0.000 title description 7
- 239000000126 substance Substances 0.000 claims description 43
- 230000000843 anti-fungal effect Effects 0.000 claims description 16
- 229940121375 antifungal agent Drugs 0.000 claims description 14
- 210000003491 skin Anatomy 0.000 claims description 12
- 210000000434 stratum corneum Anatomy 0.000 claims description 11
- OWEGWHBOCFMBLP-UHFFFAOYSA-N 1-(4-chlorophenoxy)-1-(1H-imidazol-1-yl)-3,3-dimethylbutan-2-one Chemical group C1=CN=CN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 OWEGWHBOCFMBLP-UHFFFAOYSA-N 0.000 claims description 8
- 229960003344 climbazole Drugs 0.000 claims description 8
- 229920002261 Corn starch Polymers 0.000 claims description 7
- 239000008120 corn starch Substances 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
- 206010040880 Skin irritation Diseases 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 5
- 230000036556 skin irritation Effects 0.000 claims description 5
- 231100000475 skin irritation Toxicity 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 5
- 206010042566 Superinfection Diseases 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 2
- 235000011437 Amygdalus communis Nutrition 0.000 description 2
- 235000020224 almond Nutrition 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940069780 barley extract Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Description
DESCRI Z IONE DESCRIPTION
La presente invenzione è relativa ad una composizione dermocosmetica per l'uso in dermatologia e in cosmetica, in particolare per il trattamento degli stati di irritazione cutanea associati o meno a stati di sovra-infezione derivanti da alterazioni specifiche della cute e specificamente dello strato corneo. The present invention relates to a dermocosmetic composition for use in dermatology and cosmetics, in particular for the treatment of skin irritation states associated or not with superinfection states deriving from specific alterations of the skin and specifically of the stratum corneum.
È noto l'uso in campo farmaceutico di sostanze ant imicotiche . L'uso farmaceutico di queste sostanze è regolato da disposizioni di legge. È nota, in particolare, l'attività antimicotica a varie concentrazioni del climbazolo. The use in the pharmaceutical field of anti-fungal substances is known. The pharmaceutical use of these substances is regulated by law. In particular, the antifungal activity at various concentrations of climbazole is known.
In campo dermatologico e cosmetico, le sostanze antimicotiche in genere e il climbazolo in particolare sono usate per esempio in certi shampoo. In the dermatological and cosmetic field, antifungal substances in general and climbazole in particular are used for example in certain shampoos.
D'altra parte, in campo cosmetico, vale a dire in un settore non soggetto alla legislazione che regola le formulazioni farmaceutiche, non sono al momento disponibili composizioni dermocosmetiche, che possano essere impiegate per il trattamento di stati di irritazione cutanea associati a stati di sovrainfezione e/o disepitelizzazione cutanea e mucosa, come ad esempio (caso relativamente comune) nell'infezione da candida. On the other hand, in the cosmetic field, i.e. in a sector not subject to the legislation that regulates pharmaceutical formulations, there are currently no dermocosmetic compositions available, which can be used for the treatment of skin irritation states associated with superinfection states. and / or skin and mucosal de-epithelialization, such as (relatively common case) in candida infection.
In questi casi, dunque, è necessario usare prodotti in pasta o comunque contenenti polveri adsorbenti associati a farmaci antimicotici topici diversi. Attualmente l'impiego di tali combinazioni di prodotti è scarsamente soddisfacente, non solo in termini di efficacia ma anche per praticità d'uso e considerazioni estetiche, in quanto la loro applicazione è molto visibile ed è causa di macchie sugli indumenti. In these cases, therefore, it is necessary to use products in paste or in any case containing adsorbent powders associated with different topical antifungal drugs. Currently, the use of such product combinations is scarcely satisfactory, not only in terms of effectiveness but also for practicality of use and aesthetic considerations, as their application is very visible and causes stains on clothing.
È uno scopo della presente invenzione quello di superare gli inconvenienti evidenziati in precedenza delle procedure attualmente applicate; in particolare, è uno scopo dell'invenzione quella di fornire una composizione dermocosmetica ad effetto lenitivo che possa essere efficacemente impiegata anche in caso di sovra-infezioni . It is an object of the present invention to overcome the drawbacks highlighted above in the procedures currently applied; in particular, it is an object of the invention to provide a dermocosmetic composition with a soothing effect that can be effectively used even in case of over-infections.
In accordo con tali scopi, la presente invenzione è relativa ad una composizione dermocosmetica, in particolare per il trattamento degli stati di irritazione cutanea eventualmente associati a stati di sovra-infezione derivanti da alterazioni specifiche della cute e specificamente dello strato corneo, caratterizzata dal fatto di comprendere almeno una sostanza antimicotica associata ad una sostanza riepitalizzante . In accordance with these purposes, the present invention relates to a dermocosmetic composition, in particular for the treatment of skin irritation states possibly associated with over-infection states deriving from specific alterations of the skin and specifically of the stratum corneum, characterized by the fact of comprise at least one antifungal substance associated with a re-epitalizing substance.
Secondo una preferita forma di attuazione, la composizione del trovato comprende inoltre, in associazione con la sostanza antimicotica e la sostanza riepitalizzante, una sostanza dermoprotettiva, ad esempio amido di mais. According to a preferred embodiment, the composition of the invention further comprises, in association with the antifungal substance and the re-epitalizing substance, a dermoprotective substance, for example corn starch.
Preferibilmente, la sostanza antimicotica è climbazolo, la sostanza riepitalizzante è acido jaluronico o un suo sale (jaluronato) e l'eventuale sostanza dermoprotettiva è amido di mais. Preferably, the antifungal substance is climbazole, the re-epitalizing substance is hyaluronic acid or one of its salt (hyaluronate) and the possible skin protective substance is corn starch.
In particolare, se la sostanza antimicotica è climbazolo è usata a concentrazioni comprese tra circa 0,05% e circa 1% e preferibilmente tra circa 0,2% e circa 0,6%; se la sostanza riepitelizzante è acido jaluronico è usata a concentrazioni comprese tra circa 0,05% e circa 1% e preferibilmente tra circa 0,05% e circa 0,5%; se la sostanza dermoprotettiva è amido di mais è usata a concentrazioni comprese tra circa 1% e circa 6%, e preferibilmente tra circa 2% e circa 5%. In particular, if the antifungal substance is climbazole it is used at concentrations comprised between about 0.05% and about 1% and preferably between about 0.2% and about 0.6%; if the re-epithelizing substance is hyaluronic acid it is used at concentrations comprised between about 0.05% and about 1% and preferably between about 0.05% and about 0.5%; if the dermoprotective substance is corn starch it is used at concentrations comprised between about 1% and about 6%, and preferably between about 2% and about 5%.
La composizione dermocosmetica secondo l'invenzione è in grado non solo di prevenire l'insorgenza di stati di irritazione complicate o meno da infezione, ma è anche pienamente efficace nel lenire le irritazioni, anche in presenza di sovra-infezioni, una volta che queste si sono manifestate, senza peraltro associarsi agli inconvenienti sopra descritti per i prodotti attualmente in uso. The dermocosmetic composition according to the invention is able not only to prevent the onset of irritation states complicated or not by infection, but is also fully effective in soothing irritations, even in the presence of over-infections, once these have are manifested, without however associating with the drawbacks described above for the products currently in use.
L'associazione tra una sostanza antimicotica ed una sostanza riepitalizzante, ed eventualmente una sostanza dermoprotettiva, in accordo all'invenzione consegue effetti che vanno al di là della semplice somma di effetti che ci si aspetterebbe dai singoli componenti, in quanto la composizione del trovato, oltre ad non causare i problemi pratici ed estetici evidenziati in precedenza e che invece presentano i prodotti noti, è efficace a basse concentrazioni di sostanza antimicotica tali da renderla idonea all'uso dermocosmetico . The association between an antifungal substance and a re-epitalizing substance, and possibly a skin-protective substance, according to the invention, achieves effects that go beyond the simple sum of effects that would be expected from the individual components, since the composition of the invention, in addition to not causing the practical and aesthetic problems highlighted above and that the known products present, it is effective at low concentrations of antifungal substance such as to make it suitable for dermocosmetic use.
Inoltre, la composizione del trovato si è rivelata efficace per il trattamento degli stati di irritazione con eventuale sovra-infezione derivanti da alterazioni specifiche della cute e in particolare dello strato corneo cutaneo, essendo in grado di mantenere, ripristinare e/o migliorare la funzionalità di barriera dello strato corneo. Furthermore, the composition of the invention has proved to be effective for the treatment of irritation states with possible over-infection deriving from specific alterations of the skin and in particular of the cutaneous horny layer, being able to maintain, restore and / or improve the functionality of barrier of the stratum corneum.
L'invenzione è dunque relativa, in termini generali, all'uso di una associazione di una sostanza antimicotica e di una sostanza riepitalizzante, ed eventualmente di una sostanza dermoprotettiva, ad un pH acido tamponato, come composizione dermocosmetica per il trattamento degli stati di irritazione con eventuale sovra-infezione derivanti da alterazioni specifiche della cute e in particolare dello strato corneo, cioè dello strato più superficiale dell'epidermide. The invention therefore relates, in general terms, to the use of an association of an antifungal substance and a re-epitalizing substance, and possibly of a dermoprotective substance, at a buffered acid pH, as a dermocosmetic composition for the treatment of irritation states. with possible over-infection deriving from specific alterations of the skin and in particular of the stratum corneum, ie the most superficial layer of the epidermis.
È stato infatti constatato che la composizione del trovato ha un effetto benefico sulla biochimica dello strato corneo che, sebbene formato in prevalenza da cellule in sfaldamento prive di nucleo, ha tuttavia una propria attività metabolica ed enzimatica; se tale attività viene compromessa, lo strato corneo non è più capace di assicurare le proprie funzioni tipiche, in particolare una corretta desquamazione e un'efficace protezione dei tessuti sottostanti (effetto barriera). It has in fact been found that the composition of the invention has a beneficial effect on the biochemistry of the stratum corneum which, although mainly formed by cleaving cells without a nucleus, nevertheless has its own metabolic and enzymatic activity; if this activity is compromised, the stratum corneum is no longer able to ensure its typical functions, in particular correct desquamation and effective protection of the underlying tissues (barrier effect).
A differenza dell'approccio tradizionale, dunque, che mira al trattamento degli strati profondi dell'epidermide e soprattutto della cute, la composizione del trovato è più mirata al trattamento dello strato corneo, più superficiale, sovvertendo il concetto fino ad ora adottato di trattare gli stati di irritazione cutanea mirando esclusivamente agli strati profondi, in quanto spesso gli stati di irritazione derivano principalmente alterazioni primitive dello strato corneo. Unlike the traditional approach, therefore, which aims at the treatment of the deep layers of the epidermis and above all of the skin, the composition of the invention is more aimed at the treatment of the stratum corneum, more superficial, subverting the concept adopted until now to treat the states of skin irritation aiming exclusively at the deep layers, as often the states of irritation derive mainly from primitive alterations of the stratum corneum.
Preferibilmente, ma non esclusivamente, la composizione è in forma di emulsione acquosa; la composizione può essere comunque preparata in forma diversa, per esempio, oltre che in emulsione (sia del tipo A/O, acqua in olio, sia del tipo O/A, olio in acqua), in forma di gel, polvere, lozione, schiuma, cerotto liquido, garza, eccetera; le varie forme di somministrazione possono essere realizzate sia con tecnologie standard, sia con tecnologie innovative tipo nanotecnologia . Preferably, but not exclusively, the composition is in the form of an aqueous emulsion; the composition can however be prepared in different form, for example, as well as in emulsion (both of the type A / O, water in oil, and of the type O / A, oil in water), in the form of gel, powder, lotion, foam, liquid patch, gauze, etc. the various forms of administration can be carried out both with standard technologies and with innovative technologies such as nanotechnology.
Secondo un aspetto particolarmente importante dell'invenzione, la composizione ha pH acido. According to a particularly important aspect of the invention, the composition has an acid pH.
In particolare, la composizione ha pH compreso tra circa 5,5 e circa 7,0 e preferibilmente compreso tra circa 6,5 e circa 6,8. In particular, the composition has a pH between about 5.5 and about 7.0 and preferably between about 6.5 and about 6.8.
Allo scopo di mantenere il pH ai valori prestabiliti, la composizione comprende un sistema tampone, per esempio un sistema tampone fosfato. In order to maintain the pH at predetermined values, the composition comprises a buffer system, for example a phosphate buffer system.
La composizione comprende poi opzionalmente una o più sostanze scelte nel gruppo costituito da: ristrutturanti lipidici, emulsionanti naturali, sostanze filmogene idroresistenti, sostanze lenitive. The composition then optionally includes one or more substances selected from the group consisting of: lipid restructuring agents, natural emulsifiers, water-resistant film-forming substances, soothing substances.
L'invenzione viene ulteriormente descritta nei seguenti esempi di attuazione non limitativi. The invention is further described in the following non-limiting embodiments.
È stata preparata una prima composizione in accordo al trovato contenente, in emulsione acquosa: climbazolo 0,2% A first composition was prepared according to the invention containing, in aqueous emulsion: climbazole 0.2%
sale di acido jaluronico 0,1% salt of hyaluronic acid 0.1%
amido di mais lipofilo 2,0% lipophilic corn starch 2.0%
e contenente inoltre: and also containing:
sistema tampone fosfato (pH 6,5÷6,8) phosphate buffer system (pH 6.5 ÷ 6.8)
acido 18p-glicirretico e alfa-bisabololo come sostanze lenitive; 18p-glycyrrhetic acid and alpha-bisabolol as soothing substances;
alghe rosse e idrolizzato di jojoba-estere come sostanze filmogene idroresistenti; red algae and jojoba-ester hydrolyzate as water-resistant film-forming substances;
estratto d'orzo e cera di mandorle come ristrutturanti lipidici. barley extract and almond wax as lipid restructuring agents.
È stata preparata una seconda composizione contenente, sempre in emulsione acquosa: A second composition was prepared containing, again in aqueous emulsion:
climbazolo 0,5% climbazole 0.5%
sale di acido jaluronico 0,1% salt of hyaluronic acid 0.1%
amido di mais lipofilo 5% lipophilic corn starch 5%
e contenente inoltre.· and also containing.
sistema tampone fosfato (pH 6,5÷6,8) phosphate buffer system (pH 6.5 ÷ 6.8)
acido 18p-glicirretico e alfa-bisabololo; tocoferil acetato; 18p-glycyrrhetic acid and alpha-bisabolol; tocopheryl acetate;
acido linoleico; linoleic acid;
cera di mandorle. almond wax.
Sono state preparate ulteriori composizioni simili a quelle descritte in precedenza, sia in forma di emulsioni acquose sia in diversa forma, variando la concentrazione di climbazolo (da circa 0,05% fino a circa 1%) e/o di sale di acido jaluronico (tra circa 0,05% e circa 1%) e/o di amido di mais (fino a circa 6%), oltre che degli ulteriori componenti. Further compositions similar to those described above have been prepared, both in the form of aqueous emulsions and in different forms, varying the concentration of climbazole (from about 0.05% to about 1%) and / or of hyaluronic acid salt ( between about 0.05% and about 1%) and / or corn starch (up to about 6%), as well as the other components.
Sono stati anche variati i sistemi tampone per conferire alle composizioni valori di pH compresi tra circa 5,5 e circa 7,0. Buffer systems have also been varied to give the compositions pH values ranging from about 5.5 to about 7.0.
Tutte le composizioni si sono dimostrate efficaci sia nel trattamento preventivo sia in quello protettivo degli stati di irritazione con eventuale sovrainfezione derivanti da alterazioni specifiche della cute e in particolare dello strato corneo. All the compositions have proved effective both in the preventive and in the protective treatment of irritation states with possible superinfection deriving from specific alterations of the skin and in particular of the stratum corneum.
Claims (16)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20060050 ITMI20060050A1 (en) | 2006-01-13 | 2006-01-13 | DERMOCOSMETIC COMPOSITION IN PARTICULAR FOR THE TREATMENT OF CUTANEOUS IRRITATION STATES THAT MAY BE ASSOCIATED WITH STATES OF OVER-INFECTION DERIVED FROM DSA SPECIFIC SKIN ALTERATIONS AND SPECIFICALLY OF THE CORNEO STATE |
| PCT/IB2007/000089 WO2007080511A2 (en) | 2006-01-13 | 2007-01-12 | Dermocosmetic composition comprising at least one antimycotic substance combined with a reepithelizing substance |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20060050 ITMI20060050A1 (en) | 2006-01-13 | 2006-01-13 | DERMOCOSMETIC COMPOSITION IN PARTICULAR FOR THE TREATMENT OF CUTANEOUS IRRITATION STATES THAT MAY BE ASSOCIATED WITH STATES OF OVER-INFECTION DERIVED FROM DSA SPECIFIC SKIN ALTERATIONS AND SPECIFICALLY OF THE CORNEO STATE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITMI20060050A1 true ITMI20060050A1 (en) | 2007-07-14 |
Family
ID=38256690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ITMI20060050 ITMI20060050A1 (en) | 2006-01-13 | 2006-01-13 | DERMOCOSMETIC COMPOSITION IN PARTICULAR FOR THE TREATMENT OF CUTANEOUS IRRITATION STATES THAT MAY BE ASSOCIATED WITH STATES OF OVER-INFECTION DERIVED FROM DSA SPECIFIC SKIN ALTERATIONS AND SPECIFICALLY OF THE CORNEO STATE |
Country Status (2)
| Country | Link |
|---|---|
| IT (1) | ITMI20060050A1 (en) |
| WO (1) | WO2007080511A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011087319A1 (en) * | 2011-11-29 | 2013-05-29 | Henkel Ag & Co. Kgaa | Cosmetic use of climbazole |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1534070A4 (en) * | 2002-08-20 | 2008-07-09 | Doren M Pinnel | Methods for treating fungal infections |
-
2006
- 2006-01-13 IT ITMI20060050 patent/ITMI20060050A1/en unknown
-
2007
- 2007-01-12 WO PCT/IB2007/000089 patent/WO2007080511A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007080511A3 (en) | 2007-12-13 |
| WO2007080511A2 (en) | 2007-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2794005T3 (en) | Cosmetic or pharmaceutical moisturizing ingredient | |
| JP5388568B2 (en) | Compositions and methods for treating acne | |
| WO2009017369A3 (en) | Compositions for skin protection and improvement of skin diseases containing the dibenzo-p-dioxine derivatives | |
| JP2013521300A (en) | Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds | |
| JP2016020379A (en) | Photoaging inhibitor and inhibitor for skin thinning | |
| CN104853753A (en) | Formulations comprising idebenone, n-acetyl-s-farnesyl-l-cysteine and ergothioneine and uses thereof | |
| BRPI1004113A2 (en) | benzoyl peroxide composition for skin treatment | |
| US20080076831A1 (en) | Hemorrhoid reliever and method of use | |
| JP6346962B2 (en) | Cosmetic composition for hydrating the skin | |
| BRPI0518554A2 (en) | use of a pde3 inhibitor | |
| Patel et al. | Nanomedicine-fortified cosmeceutical serums for the mitigation of psoriasis and acne | |
| ES2573478T3 (en) | Use of compositions comprising at least one lignan and / or neolignan to modulate the testosterone rate | |
| WO2012042970A1 (en) | Prophylactic or therapeutic agent for atopic dermatitis, and preparation for external application | |
| ES2392180T3 (en) | Combinations of active substances of glycosyl glycosides and creatine and / or creatinine | |
| EP3058945B1 (en) | Pharmaceutical compositions and formulations for topical application with astringent and antimicrobial effect | |
| ES2606233T3 (en) | Compositions for the treatment of rosacea comprising chitosan and a dicarboxylic acid amide | |
| ITMI20060050A1 (en) | DERMOCOSMETIC COMPOSITION IN PARTICULAR FOR THE TREATMENT OF CUTANEOUS IRRITATION STATES THAT MAY BE ASSOCIATED WITH STATES OF OVER-INFECTION DERIVED FROM DSA SPECIFIC SKIN ALTERATIONS AND SPECIFICALLY OF THE CORNEO STATE | |
| EP3677264A1 (en) | Composition for preventing or treating atopic dermatitis | |
| US9827176B2 (en) | Antifungal deodorant | |
| US20100098732A1 (en) | Methods, processes and compositions comprising the protein calmodulin (cam) for treatment of damaged or aging skin, and/or hair loss | |
| US20150182442A1 (en) | Traditional chinese medicine composition that has the effect of soothing and cleaning face | |
| JP2013155170A (en) | Skin lotion | |
| WO2019189742A1 (en) | Composition for external application containing ascorbic acid and/or salt thereof | |
| WO2016159184A1 (en) | Topical composition for amelioration of acne vulgaris | |
| ES2262527T3 (en) | COMPOSITION OF TWO COMPONENTS FOR COSMETIC OR PHARMACEUTICAL USE. |